4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/PF-573228/25mg/406126
商品详细MedKoo/PF-573228/25mg/406126
MedKoo/PF-573228/25mg/406126
MedKoo/PF-573228/25mg/406126
商品编号: 406126
品牌: MedKoo
市场价: ¥3000.00
美元价: 1800.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

PF-573228
new
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406126

CAS#:869288-64-2

Description:PF-573228 is a potent and selective inhibitor of focal adhesion kinase (FAK) (IC50= 4 nM). Displays 50 - 250-fold selectivity for FAK over other protein kinases. PF573228 was recognized to affect cell adhesion and migration in many types of cells.

Price and Availability

SizePriceShipping out timeQuantity
25mgUSD 150Same day
50mgUSD 250Same day
100mgUSD 450Same day
200mgUSD 750Same day
500mgUSD 1250Same day
1gUSD 1950Same day
2gUSD 39502 Weeks
5gUSD 66502 Weeks
10gUSD 99502 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

PF-573228,purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406126Name: PF-573228CAS#: 869288-64-2Chemical Formula: C22H20F3N5O3SExact Mass: 491.12389Molecular Weight: 491.48611Elemental Analysis: C, 53.76; H, 4.10; F, 11.60; N, 14.25; O, 9.77; S, 6.52

Synonym:PF573228; PF 573228; PF-573228; PF573,228; PF 573,228; PF-573,228.

IUPAC/Chemical Name:3,4-Dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2(1H)-quinolinone

InChi Key:HESLKTSGTIBHJU-UHFFFAOYSA-N

InChi Code:InChI=1S/C22H20F3N5O3S/c1-34(32,33)16-4-2-3-13(9-16)11-26-20-17(22(23,24)25)12-27-21(30-20)28-15-6-7-18-14(10-15)5-8-19(31)29-18/h2-4,6-7,9-10,12H,5,8,11H2,1H3,(H,29,31)(H2,26,27,28,30)

SMILES Code:O=C1NC2=C(C=C(NC3=NC=C(C(F)(F)F)C(NCC4=CC=CC(S(=O)(C)=O)=C4)=N3)C=C2)CC1

Technical Data

Appearance:
White solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#BBC50727

QC Data:
View QC data: current batch, Lot# BBC50727

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Melo TG, Tucci AR, Nogueira AR, Meirelles Mde N,Pereira MC. The involvement of FAK and Src in the invasion ofcardiomyocytes by Trypanosoma cruzi. Exp Parasitol. 2014 Apr;139:49-57.doi: 10.1016/j.exppara.2014.02.008. Epub 2014 Feb 25. PubMed PMID:24582948.

2: Xu B, Ju Y, Song G. Role of p38, ERK1/2, focal adhesion kinase, RhoA/ROCKand cytoskeleton in the adipogenesis of human mesenchymal stem cells. JBiosci Bioeng. 2014 May;117(5):624-31. doi:10.1016/j.jbiosc.2013.10.018. Epub 2013 Dec 9. PubMed PMID: 24331979.

3: Beauséjour M, Thibodeau S, Demers MJ, Bouchard V, Gauthier R,Beaulieu JF, Vachon PH. Suppression of anoikis in human intestinalepithelial cells: differentiation state-selective roles of α2β1, α3β1,α5β1, and α6β4 integrins. BMC Cell Biol. 2013 Dec 1;14:53. doi:10.1186/1471-2121-14-53. PubMed PMID: 24289209.

4: Chan D, Thomas CJ, Taylor VJ, Burke RD. Integrins on eggs: focaladhesion kinase is activated at fertilization, forms a complex withintegrins, and is necessary for cortex formation and cell cycleinitiation. Mol Biol Cell. 2013 Nov;24(21):3472-81. doi:10.1091/mbc.E13-03-0148. Epub 2013 Aug 28. PubMed PMID: 23985318; PubMedCentral PMCID: PMC3814141.

5: Wiemer AJ, Wernimont SA, Cung TD, Bennin DA, Beggs HE, HuttenlocherA. The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ Tcell activation. Biochem Pharmacol. 2013 Sep 15;86(6):770-81. doi:10.1016/j.bcp.2013.07.024. Epub 2013 Aug 5. PubMed PMID: 23928188;PubMed Central PMCID: PMC3762933.

6: Kline ER, Shupe J, Gilbert-Ross M, Zhou W, Marcus AI. LKB1 repressesfocal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulateFAK site maturation and directional persistence. J Biol Chem. 2013 Jun14;288(24):17663-74. doi: 10.1074/jbc.M112.444620. Epub 2013 May 1.PubMed PMID: 23637231; PubMed Central PMCID: PMC3682567.

7: Moore SW, Zhang X, Lynch CD, Sheetz MP. Netrin-1 attracts axonsthrough FAK-dependent mechanotransduction. J Neurosci. 2012 Aug22;32(34):11574-85. doi: 10.1523/JNEUROSCI.0999-12.2012. PubMed PMID:22915102; PubMed Central PMCID: PMC3461192.

8: Hori Y, Kashimoto T, Yonezawa T, Sano N, Saitoh R, Igarashi S,Chikazawa S, Kanai K, Hoshi F, Itoh N, Higuchi S. Matrixmetalloproteinase-2 stimulates collagen-I expression throughphosphorylation of focal adhesion kinase in rat cardiac fibroblasts. AmJ Physiol Cell Physiol. 2012 Nov 1;303(9):C947-53. doi:10.1152/ajpcell.00401.2011. Epub 2012 Aug 22. PubMed PMID: 22914642.

9: Tse KW, Lin KB, Dang-Lawson M, Guzman-Perez A, Aspnes GE, BuckbinderL, Gold MR. Small molecule inhibitors of the Pyk2 and FAK kinasesmodulate chemoattractant-induced migration, adhesion and Akt activationin follicular and marginal zone B cells. Cell Immunol. 2012Jan-Feb;275(1-2):47-54. doi: 10.1016/j.cellimm.2012.03.002. Epub 2012Mar 29. PubMed PMID: 22507871.

10: Guessous F, Yang Y, Johnson E, Marcinkiewicz L, Smith M, Zhang Y,Kofman A, Schiff D, Christensen J, Abounader R. Cooperation betweenc-Met and focal adhesion kinase family members in medulloblastoma andimplications for therapy. Mol Cancer Ther. 2012 Feb;11(2):288-97. doi:10.1158/1535-7163.MCT-11-0490. Epub 2011 Dec 21. PubMed PMID: 22188814;PubMed Central PMCID: PMC3277676.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。